PAK4 and non-Hodgkin lymphoma: A first-in-human phase 1 study of KPT-9274, a first-in-class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or non-Hodgkin’s lymphoma is ongoing (38).